Literature DB >> 27680756

Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.

Manuel Kussmann1, Linda Schuster1, Sarah Wrenger1, Petra Pichler2, Gottfried Reznicek3, Heinz Burgmann1, Wolfgang Poeppl1,4, Markus Zeitlinger5, Martin Wiesholzer2.   

Abstract


BACKGROUND: Peritonitis is a major problem among patients on peritoneal dialysis (PD). The influence of diverse PD fluids on the activity of frequently used antibiotics has been insufficiently investigated. Thus, the present study set out to investigate the impact of different PD fluids on the activity of cefepime, ciprofloxacin, ertapenem, meropenem, and tobramycin against Escherichia coli. ♦
METHODS: Time-kill curves in 4 different PD fluids (Dianeal PDG4, Extraneal, Nutrineal PD4 and Physioneal 40, all Baxter Healthcare Corp., Deerfield, IL, USA) were performed over 24 hours with 4 different concentrations (1 × minimum inhibitory concentration [MIC], 4 × MIC, 8 × MIC, 30 × MIC) of each antibiotic evaluated and without antibiotics as control. Cation-adjusted Mueller Hinton broth (CA-MHB) was used as comparator solution. ♦
RESULTS: In all PD fluids investigated, bacterial growth and antimicrobial activity of all antibiotics tested was significantly reduced compared with the CA-MHB comparator solution. Except at high concentrations of 30 × MIC, cefepime, ertapenem and meropenem demonstrated a strongly reduced activity in all PD fluids investigated. Ciprofloxacin and tobramycin were highly active and bactericidal in all PD fluids and demonstrated dose-dependent activity. ♦
CONCLUSION: The antimicrobial activity of cefepime, ertapenem and meropenem is limited or even nullified in certain PD fluids in vitro, whereas ciprofloxacin and tobramycin show excellent activity. The choice of PD fluids can impact the activity of antimicrobial agents and might influence microbiological outcome. Further studies are required to verify the clinical relevance of our findings.
Copyright © 2016 International Society for Peritoneal Dialysis.

Entities:  

Keywords:  Antibiotics; infection; peritoneal dialysis solutions; peritonitis; time-kill curves

Mesh:

Substances:

Year:  2016        PMID: 27680756      PMCID: PMC5174874          DOI: 10.3747/pdi.2015.00161

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  31 in total

1.  Impact of various peritoneal dialysis solutions on the growth of common bacterial and yeast pathogens.

Authors:  Selma Tobudic; Christina Kratzer; Wolfgang Poeppl; Andreas Vychytil; Heinz Burgmann
Journal:  Perit Dial Int       Date:  2011 Nov-Dec       Impact factor: 1.756

2.  Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis.

Authors:  P J Vlaar; M van Hulst; C A Benne; W M Janssen
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

3.  Intraperitoneal meropenem administration: a possible alternative to the intravenous route.

Authors:  C Van Ende; M Tintillier; C Cuvelier; G Migali; J M Pochet
Journal:  Perit Dial Int       Date:  2010 Mar-Apr       Impact factor: 1.756

4.  Stability of drug additives to peritoneal dialysate.

Authors:  G R Bailie; M P Kane
Journal:  Perit Dial Int       Date:  1995 Oct-Dec       Impact factor: 1.756

5.  Evolution of microbiological trends and treatment outcomes in peritoneal dialysis-related peritonitis.

Authors:  S-T Huang; Y-W Chuang; C-H Cheng; M-J Wu; C-H Chen; T-M Yu; K-H Shu
Journal:  Clin Nephrol       Date:  2011-05       Impact factor: 0.975

6.  32 years' experience of peritoneal dialysis-related peritonitis in a university hospital.

Authors:  Sadie van Esch; Raymond T Krediet; Dirk G Struijk
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

7.  The recommendations from the International Society for Peritoneal Dialysis for Peritonitis Treatment: a single-center historical comparison.

Authors:  Margarete M Silva; Roberto Pecoits-Filho; Carla S Rocha; Andréa E M Stinghen; Maria A Pachaly; Marcelo M Nascimento; Rodrigo P Campos; Sirlene Sauthier; Roseana Fuerbringer; Miguel C Riella
Journal:  Adv Perit Dial       Date:  2004

8.  The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth.

Authors:  E Tuomanen; R Cozens; W Tosch; O Zak; A Tomasz
Journal:  J Gen Microbiol       Date:  1986-05

9.  Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients.

Authors:  Quresh Khairullah; Robert Provenzano; Jukaku Tayeb; Aijaz Ahmad; Radhakrishnan Balakrishnan; Linda Morrison
Journal:  Perit Dial Int       Date:  2002 May-Jun       Impact factor: 1.756

10.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

View more
  3 in total

1.  Compatibility of fosfomycin with different commercial peritoneal dialysis solutions.

Authors:  M Kussmann; A Baumann; S Hauer; P Pichler; M Zeitlinger; M Wiesholzer; H Burgmann; W Poeppl; G Reznicek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-06       Impact factor: 3.267

2.  Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions.

Authors:  Manuel Kussmann; Alexander Ferth; Markus Obermüller; Petra Pichler; Markus Zeitlinger; Martin Wiesholzer; Heinz Burgmann; Wolfgang Poeppl; Gottfried Reznicek
Journal:  Sci Rep       Date:  2019-04-24       Impact factor: 4.379

3.  Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa.

Authors:  Manuel Kussmann; Stefan Hauer; Petra Pichler; Gottfried Reznicek; Heinz Burgmann; Wolfgang Poeppl; Markus Zeitlinger; Martin Wiesholzer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-15       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.